

# Contents

1. Introduction	1
2. Global leprosy situation in 1997	3
2.1 Estimated cases	3
2.2 Registered cases	3
2.3 Detection of cases	3
2.4 Achievements with MDT	5
3. Epidemiology	5
3.1 Definition of a case of leprosy	5
3.2 Diagnosis of leprosy	6
3.3 Single-lesion leprosy	6
3.4 Clinical classification for control programmes	7
3.5 Prevalence	8
3.6 Undetected cases	8
3.7 Case detection and incidence	9
3.8 Subclinical infection	9
3.9 Examination of household contacts	10
3.10 Reservoirs of infection	10
3.11 Impact of the human immunodeficiency virus (HIV) epidemic	10
3.12 Impact of BCG vaccination	10
3.13 Disability burden	11
3.14 Simulation modelling	11
3.15 Lepromin test	11
4. Chemotherapy	11
4.1 Currently available drugs	11
4.1.1 Dapsone	12
4.1.2 Rifampicin	12
4.1.3 Clofazimine	12
4.1.4 Ofloxacin	13
4.1.5 Minocycline	13
4.1.6 Clarithromycin	13
4.1.7 Reporting of adverse drug reactions	14
4.2 Standard MDT regimens	14
4.3 Shortening the duration of MDT for multibacillary leprosy	15
4.3.1 Bactericidal effect of the dapsone–clofazimine component of the MDT regimen	15
4.3.2 Field trials and clinical studies	16
4.4 Flexible delivery system for MDT	17
4.5 Alternative MDT regimens	18
4.5.1 Regimen for single-lesion paucibacillary leprosy	18
4.5.2 Immunotherapy with chemotherapy	19
4.5.3 Other regimens for special situations	19
4.6 Drug resistance	20
4.7 Relapse	20

4.8	Patients who attend for treatment irregularly and defaulters	21
4.9	Delivery of MDT drugs and drug supply logistics	21
<b>5.</b>	<b>Management of reactions and neuritis</b>	<b>22</b>
5.1	Management of reactions	22
5.2	Management of neuritis	23
<b>6.</b>	<b>Disabilities and rehabilitation</b>	<b>24</b>
6.1	Magnitude of the problem	24
6.2	WHO disability grading system for leprosy	25
6.3	Assessment of disabilities	25
6.4	Prevention and improvement of disabilities	26
6.5	Strategies to solve the problem	26
6.6	Rehabilitation	27
<b>7.</b>	<b>The global strategy for the elimination of leprosy by the year 2000</b>	<b>27</b>
7.1	Global strategy for the elimination of leprosy	28
7.1.1	Capacity-building within integrated programmes	28
7.1.2	Reaching pockets of high leprosy prevalence	28
7.1.3	Reaching special population groups	28
7.1.4	Leprosy in urban areas	29
7.1.5	Coordination between agencies	29
7.1.6	Leprosy and human rights	29
7.2	Global strategy beyond the year 2000	30
7.2.1	Leprosy elimination at intermediate levels	30
7.2.2	Countries with a low prevalence of leprosy	30
7.2.3	Sustainability of antileprosy activities and other issues	31
<b>8.</b>	<b>Monitoring the elimination of leprosy</b>	<b>31</b>
<b>9.</b>	<b>Integration of antileprosy activities within general health services</b>	<b>32</b>
9.1	Combined programmes	33
9.2	Fully integrated programmes	33
9.3	Referral services and specialized support	34
<b>10.</b>	<b>Community action and participation</b>	<b>34</b>
10.1	Approaches to create awareness and support	34
10.2	Promoting community participation	35
10.3	Role of local nongovernmental organizations and community groups	35
<b>11.</b>	<b>Research priorities</b>	<b>35</b>
11.1	Research to improve patient care	36
11.1.1	Improving the implementation of MDT regimens	36
11.1.2	Nerve damage	36
11.1.3	Management of reactions and neuritis	36
11.2	Research on post-elimination strategies	36
11.2.1	Epidemiological research	36
11.2.2	New developments in chemotherapy	37
11.2.3	Basic research	37

12. Conclusions and recommendations	37
Acknowledgements	38
References	39